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INTRODUCTION
Giant cell arteritis (GCA), also known as temporal arteritis, is a vascular disorder of medium and large vessels (1). Many of the most worrying features of the disorder result from vascular inflammation involving cranial branches of the arteries originating from the aortic arch (2, 3) . Glucocorticoids have never been studied in a placebo-controlled manner in GCA, but their effectiveness is well established. Glucocorticoids may predispose to or worsen pre-existing conditions, such as osteoporosis or Type II diabetes mellitus (DM). This is a particular concern, because the disease affects postmenopausal women and older men. However, evidence for the efficacy of immunosuppressant drugs as steroidsparing agents in this disease is lacking. The results of RCTs on Methotrexate (MTX) in GCA have led to somewhat divergent conclusions (4-6). Thus, more work toward the identification of effective prednisone-sparing agents is highly desirable.
We report our experience in the treatment with MMF as a steroid-sparing agent in three elderly subj b ects with new-onset GCA at high risk of long-term high-dose glucocorticoids because of DM, obesity, hypertension or osteoporosis.
MMF has been reported as a safe and well-tolerated treat a a ment in other aut u u oimmune disord r r ers aff f f ecting the older population (7) .
The diagnosis of new-onset GCA was made according to American College of Rheumatology criteria (8) and all patients underw r r ent biopsy of the temporal art r r ery r r (Fig. 1) . All patients gave their written informed consent.
Oral MMF (2 g/d / / ) was given to three patients in two separated doses.
Patients were evaluated at baseline and after treatment according to the following criteria: 1) presence of headache, abrupt onset of visual disturbances or jaw claudication; 2) sy s stemic sy s s mptoms, including feve v v r not attribut u u ab a le to infection, poly l l art r r hralgia, and poly l l my m m algia; and 3) elevated values of Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP).
Clinical evaluation and assessment of laboratory parameters were carried out weekly during the first month of treatment. Thereafter, patients were seen in the clinic every 2 weeks.
Vascular lesions were also qualitatively assessed by Doppler UltraSonography (DUS) of the temporal artery every 3 months during the follow-up (12-29 months).
Clinical characteristics at baseline
Baseline clinical charact c c erist s s ics are shown w w in Ta T T b a le 1. All the patients had a clinical history of DM in oral therapy (metformin) and hypertension needing at least three anti-hypertensive drugs (ramipril, amlodipine and hydrochlorothiazide). Two patients were obese (patients 2 and 3, Body Mass Index 32 and 41, respectively); one of them suffered from osteoporosis (T score -2.9 at Dual energy X-ray Absorptiometry) and was given alendronate sodium (70 mg/w / / eekly).
Clinical Outcome
Pat a a ient responses to MMF therapy are listed in Tab a le 1. No signs of clinical relapse was detected over a mean of 21.6 months (12-29) of follow-up.
PAT A A IENT 1
The patient's systemic symptoms resolved 2 weeks after initiation of therapy, and ESR rapidly decreased (Fig.  1) . Initial prednisone therapy was 50 mg/d / / ay associated with MMF, both administered immediately after histological confirmation of the diagnosis. After 1 month of MMF therapy, the prednisone dose could be tapered to 15 mg/d / / , and to 7.5 mg/d / / after three months. After 12 months of follow-up, the patient remained in a stable clin-
Fig. 1 -Serologic and histopathology assessment, and therapy regimen of o patients. A) Inflammation scores, Erythrocyte Sedimentation Rate (E ( ( SR) R and C-Reactive Protein (C ( ( R C C P) P of o three patients during fo f f llow-up. B) Steroid tapering regimen: chart shows mean prednisone dose in our ex e e p x erience, in comparison with dosage g g re r r cently sugg g g e g g sted. Wi W W th MM M M F M M a more r r ra r r pid pre r r dnisone tapering (p ( ( <0.001, with paire r r d two-sample t-tests) was achieved compared with conventional steroid dosage sugg g g ested by Dasgupta et al. (9) 9 . C) Histopathology findings in temporal artery: chronic inflammatory infiltrates consisting of o monocytes, lymphocytes associated with sporadic giant cells (a ( ( rrow) and fragmentation of o internal elastic lamina.
Inflammation scores 16 Guidelines (mean) Our experience (mean) C ical condition, with no instrumental evidence of disease progression. Headache or jaw claudication attacks never recurred. DUS, performed 9 months after CGA diagnosis, showed the resolution of the previously described va v v scular lesions. DM and hypert r r ension were under control and no therapy adj d ustment was needed. At the last observ r r a v v tion (10 months aft f f er diagnosis), the patient was giv-v v en 5 mg/d / / prednisone and 2 g/d / / MMF. Fig. 1 . Fever disappeared and never re-appeared during follow-up. Aft f f er 1 month of MMF therapy, given after histological confirmation of diagnosis, the prednisone dose could be tapered to 12.5 mg in 1 month and, after 29 months of follow-up, to 5 mg. Headaches never recurred. DUS performed 9 months after diagnosis showed resolution of the previously described vascular lesions. DM and hypertension were under control and no therapy adj d ustment was needed. At the last observation (27 months after diagnosis) the patient was given 5 mg/d / / prednisone and 2 g/d / / MMF.
PAT A A IENT
2 Tw T T o weeks aft f f er initiation of therapy (starting dose 50 mg/d of prednisone associated with MMF), systemic symptoms and headaches resolved. Laboratory markers of infl f f ammat a a ion are shown w w in Fi F F g. 1. The steroid dose wa w w s halved from the initial dose after 3 weeks of therapy with MMF. A DUS ultrasonogram showed no deterioration of previously described vascular lesions during 24 months of follow-up. Prednisone was tapered to a daily dose of 10 mg wi w w thin 4 months. The pat a a ient felt l l ve v v ry r r we w w ll, and no change in diabetic or anti-hypertensive therapy was needed. At the last observation (24 months after diagnosis) the patient was given 7.5 mg/
Side-Ef E f
f f e f f cts All patients tolerated MMF without any maj a or toxicity.
DISCUSSION
Therapeutic decisions in GCA are often guided by individual patient variables, including location and severity of arterial lesions, availability of collateral circulation, nature and intensity of symptoms, and the risks of drug toxicity.
The present report shows that MMF therapy was well tolerated, could control GCA activi v v ty t t , and also allowed the prednisone doses to be tapered in a more rapid regimen compared with the recently suggested steroid reduction approach ( Fig. 1) (9) .
After 1 month of MMF, the prednisone dose could be Table 1 Positive tapered to a mean dose of 17.5 mg (12.5-25 mg), with a first-month mean reduction of more than half the initial dose. Instead, referring to recent guidelines (9) , no steroid reduction wa w w s suggested in the 3-4 we w w eks k k of glucocort r r icoid treatment. A comparable reduction of more than half the initial dose was reached only after at least 7 weeks from the initiation of therapy (Fig. 1) . MMF therapy caused a significant decrease in ESR and CRP values.
-Characteristics of o three patients with GCA C C , 1) at onset of o disease and 2) 2 under treatment with MM M M F M M at end of o fo f f llow-up.
-Onset of disease
Glucocorticoids constitute the first-line treatment for active arterial inflammation, and an initial daily dose of 40-60 mg of prednisone or its equivalent, in single or divided doses, is adequate in almost all cases of GCA (10) . Some patients respond to doses as low as 20 mg/d / / ay, but this dose is seldom used, primarily because of concern for the potential consequences of undertreatment (11) . Although remission is achieved in nearly all cases, (12, 13) , relapses during glucocorticoid tapering may occur. Glucocort r r icoid may also predispose to or worsen pre-existing conditions, such as osteoporosis, DM, hypertension and obesity as in our cases. This is a particular concern, because these diseases mainly affect postmenopausal women and older men. Therefore, other immunosuppressive drugs may be potentially added to glucocorticoids, with the aim of curbing disease progression and reducing disease and glucocorticoidrelated morbidity.
MTX is an immunosuppressant proposed for GCA treatment. The results of RCTs of MTX in GCA have led to somewhat divergent conclusions (4-6) and, taken together, the results of these trials are difficult to reconcile entirely. They have recently been the subj b ect of a formal meta-analysis (14) , according to which, adj d unctive MTX treatment for GCA reduces the risk of both first and second relapses (hazard ratios 0.65 and 0.49, respectively). By contrast, MTX does not appear to act quickly, and thus cannot be recommended as a replacement for glucocorticoids at disease onset. In such a context, more work towa w w rd r r the identificat a a ion of eff f f ectiv i i e v v prednisone-sparing agents is highly recommended (15) .
MMF has been used most oft f f en in transplant recipients, and the rationale for using MMF in patients with GCA is supported by the drug's immunosuppressive properties and its unique action in preventing lymphocyte-mediated vascular damage. Substantial evi v v dence of the use of MMF in large ve v v ssel va v v sculitis (e.g., Taka k k y a a asu art r r eritis) is report r r ed in the literature (16) . Its good safety profile may also prove valuable, thanks to its potential for steroid-sparing effect.
We based our definition of disease activity on clinical and serologic parameters. Ultrasound evaluation was also performed. However, evaluation of the clinical response in GCA is difficult to assess because no accurate definitions of disease activity and remission are available. Although subjective symptoms, laboratory data, and angiographic changes hav a a e v v been proposed to eva v v luat a a e disease status, none of them are specific.
Therefore, this is a preliminary report of three patients for whom we believed that the use of GC at the conventional dose was not recommended, due to the high metabolic risk represented by co-existing DM, hypertension, osteoporosis and obesity. In addition, although the clinical setting recommended rapid therapeutic decisions, in our opinion the absence of very severe events (such as visual disturbances/v / / isual loss) allowed us to avoid the use of high doses of glucocorticoids, potentially linked with complications in such patients. The use of a steroid-sparing agent thus was highly recommended.
All three patients reported a subj b ective benefit. During the observation period, none experienced new onset of headache or jaw a a claudication; clinical examinat a ion showed no evidence of tenderness on temporal arteritis. No patients had feve v v r, and all sy s s stemic sy s s mptoms resolv l l e v v d. In all patients, tapering of steroid therapy was achieved. All three patients completely resumed lifestyles which they had long abandoned because of their illness. Diabetes and hypertension were under control during follow-up. In any case, as GCA is a remitt t t ing and relapsing disease, we cannot exclud u u e the possibility t t that a a our pat a a ients' positive v v response may be due to spontaneous remission rather than the effect of the drug. However, the concomitant sub u j b ective v v benefit and normalization of laboratory r r data are consistent with the hypothesis that clinical improvement was due to MMF therapy associated with glucocorticoids. A longer follow-up period is needed to assess duration of remission.
In our experience, MMF prove v v d to be safe and wa w w s we w w ll tolerated. As none of the patients had leucopenia, thrombocytopenia, elevated liver enzyme levels, or gastrointestinal discomfort, the dosage of 2 g/d / / could be maintained.
However, the follow-up may have been too short; therefore sub u sequent n deve v v lopment n n of more serious adv d d e v v rse effects cannot be excluded.
CONCLUSIONS
MMF may a a be considered a steroid-sparing agent in patients with GCA. Before results of controlled trials become av a a a v v ilab a le, MMF should be considered only l l for pat a a ient n n s wh w w o do not improve or stabilize with conventional therapy or in ones for wh w w om a reduction in steroid dose is highly l l recommended, owing to co-existing conditions such as DM, osteoporosis, hypertension and obesity.
